Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New facility, new capabilities
February 2016
EDIT CONNECT

SHARING OPTIONS:

SAN DIEGO—Ajinomoto Althea Inc. (Althea) announced in late 2015 the expansion of its biological drug product manufacturing operations to include highly active materials such as antibody drug conjugates (ADCs). The new location will have dedicated areas for bioconjugation, formulation, purification, quality control and aseptic fill finish, including lyophilization. Althea will be executing services from the new facility as early as Q2 2016, with full manufacturing activities to be online in H1 2017.
 
Dr. Jason Brady, senior director and business head of ADCs, said, “Currently, there is limited capacity of high containment manufacturing in the United States. Althea is excited to make this significant expansion of our service offerings to address the needs of the ADC market as well as other highly potent products. Given our existing core capabilities in complex biologics formulation and aseptic filling, this investment in ADC and HPAPI [highly potent active pharmaceutical ingredients] fill finish manufacturing is a natural progression and logical step for Althea.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.